- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT07861386
Emulation of the MAVERICC Trial Using Specialty Oncology Electronic Health Records Databases
Emulation of the MAVERICC (NCT01374425) Trial Using Specialty Oncology Electronic Health Records Databases
This trial emulation study aims to emulate the MAVERICC trial (NCT01374425) using real-world specialty oncology electronic health record data and to investigate the concordance between the trial's original and emulated treatment effect estimates on overall survival (OS). MAVERICC was a Phase II, open-label, randomized study assessing the efficacy and safety of modified leucovorin/5-fluorouracil/ oxaliplatin plus bevacizumab (mFOLFOX6-BV) with leucovorin/5-fluorouracil/irinotecan plus bevacizumab (FOLFIRI-BV) in patients with previously untreated metastatic colorectal cancer (mCRC).
Studieöversikt
Status
Betingelser
Intervention / Behandling
Detaljerad beskrivning
Randomized controlled trials (RCTs) are generally regarded as the gold-standard of evidence for establishing efficacy of medical products. However, real-world data (RWD) are increasingly used to complement evidence from RCTs. Yet, to have confidence in the accuracy of non-interventional studies medical products and their outcomes in oncology, investigators need to know what questions can be validly answered, with which non-interventional study designs, and which analysis methods are appropriate, given the data that is available. Building on a process from the RCT DUPLICATE initiative, EmulatioN of Comparative Oncology trials with Real-world Evidence (ENCORE) is the trial emulation discussed in this protocol, which is part of the expansion project specific to oncology and aims to emulate 12 randomized oncology RCTs using multiple EHR data sources.
The purpose of this protocol is to describe the emulation of the MAVERICC trial. MAVERICC was a Phase II, open-label, randomized study assessing the efficacy and safety of modified leucovorin/5-fluorouracil/ oxaliplatin plus bevacizumab (mFOLFOX6-BV) with leucovorin/5-fluorouracil/irinotecan plus bevacizumab (FOLFIRI-BV) in patients with previously untreated metastatic colorectal cancer (mCRC).
Studietyp
Inskrivning (Faktisk)
Kontakter och platser
Studieorter
-
-
Massachusetts
-
Somerville, Massachusetts, Förenta staterna, 02145
- Brigham and Women's Hospital
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Testmetod
Studera befolkning
Adults with previously untreated metastatic colorectal cancer who initiated FOLFIRI plus bevacizumab or mFOLFOX6 plus bevacizumab as first-line treatment.
Beskrivning
Inclusion Criteria:
- Age 18 years or older at first-line study regimen initiation.
- Metastatic colorectal cancer documented in a specialty oncology electronic health record.
- Initiation of FOLFIRI plus bevacizumab or mFOLFOX6 plus bevacizumab as first-line systemic treatment for metastatic disease.
- Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 when ascertainable in the database.
Exclusion Criteria:
- Evidence of brain metastases at or before study regimen initiation.
- Prior systemic treatment for metastatic colorectal cancer.
- Adjuvant chemotherapy within 12 months before study regimen initiation.
- Another primary malignancy within five years before study regimen initiation, except cervical carcinoma in situ, basal or squamous cell skin cancer, localized prostate cancer, or ductal carcinoma in situ.
- Use of an investigational agent within 28 days before study regimen initiation.
- Other anticancer treatment during the treatment assessment window, where ascertainable in the database.
Studieplan
Hur är studien utformad?
Designdetaljer
- Observationsmodeller: COHORT
- Tidsperspektiv: RETROSPECTIVE
Kohorter och interventioner
Grupp / Kohort |
Intervention / Behandling |
|---|---|
|
Initiation of FOLFIRI plus bevacizumab
|
Observed initiation of first-line FOLFIRI (leucovorin, fluorouracil, and irinotecan) plus bevacizumab for metastatic colorectal cancer in routine care. Treatment was not assigned by this observational study.
Andra namn:
|
|
Initiation of mFOLFOX6 plus bevacizumab
|
Observed initiation of first-line mFOLFOX6 (modified leucovorin, fluorouracil, and oxaliplatin) plus bevacizumab for metastatic colorectal cancer in routine care. Treatment was not assigned by this observational study.
Andra namn:
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Time to all-cause mortality (overall survival)
Tidsram: From time of initiation of therapy through the earliest of death from any cause (the primary outcome of interest) or end of data availability (depending on the oncology registry data provider; end of data ranges from September 2023 to February 2026)
|
Hazard ratio (95% CI) |
From time of initiation of therapy through the earliest of death from any cause (the primary outcome of interest) or end of data availability (depending on the oncology registry data provider; end of data ranges from September 2023 to February 2026)
|
Samarbetspartners och utredare
Sponsor
Samarbetspartners
Utredare
- Huvudutredare: Shirley V Wang, PhD, ScM, Brigham and Women's Hospital
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
- Neoplasmer efter plats
- Neoplasmer
- Tarmsjukdomar
- Gastrointestinala neoplasmer
- Neoplasmer i matsmältningssystemet
- Matsmältningssystemets sjukdomar
- Gastrointestinala sjukdomar
- Intestinala neoplasmer
- Rektala sjukdomar
- Kolonsjukdomar
- Kolorektala neoplasmer
- Aminosyror, peptider och proteiner
- Proteiner
- Antikroppar, monoklonal, humaniserad
- Antikroppar, monoklonal
- Antikroppar
- Immunglobuliner
- Immunoproteiner
- Blodproteiner
- Serumglobuliner
- Globuliner
- Bevacizumab
Andra studie-ID-nummer
- 2022P002556-ENC-MAVERICC
- 75F40122C00181 (Annat bidrag/finansieringsnummer: Food and Drug Administration)
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .